Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Tuesday 6 February 2018, 10:00-12:40

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Professor Gary McVeigh – Chair Present for all notes
2. Dr Lindsay Smith – Vice Chair Present for all notes
3. Dr Nabeel Alsindi Present for all notes
4. Dr Aomesh Bhatt Present for all notes
5. Professor David Bowen Present for all notes
6. Mrs Susan Dutton Present for all notes
7. Professor Rachel Elliott Present for all notes
8. Mrs Gillian Ells Present for all notes
9. Rebecca Harmston Present for all notes
10. Dr Robert Hodgson Present for all notes
11. Dr Bernard Khoo Present for all notes
12. Dr David Meads Present for all notes
13. Mr Malcolm Oswald Present for all notes
14. Professor Oluwafemi Oyebode Present for all notes
15. Dr Paula Parvulescu Present for all notes
16. Nigel Westwood (Committee B) Present for all notes

In attendance:
Sophie Beale Assessment Group representative, Liverpool Reviews and Implementation Group Present for notes 1 to 13
Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes
Dr Peter Clark CDF Clinical Lead, NHS England Present for notes 9 to 27
Ross Dent Technical Analyst, National Institute for Health and Care Excellence Present for notes 17 to 27
Henry Edwards Technical Analyst, National Institute for Present for all notes
<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Nominated by</th>
<th>Present for Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Martin Forster</td>
<td>Clinical Senior Lecturer and Honorary Consultant Medical Oncologist, Clinical Expert, nominated by NCRI-RCP-RCR-ACP</td>
<td>1 to 13</td>
</tr>
<tr>
<td>Chris Griffiths</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>All</td>
</tr>
<tr>
<td>Lesley Holland</td>
<td>Macmillan Lung Cancer Clinical Nurse Specialist, Patient Expert, nominated by National Lung Cancer Forum for Nurses</td>
<td>1 to 13</td>
</tr>
<tr>
<td>Helen Knight</td>
<td>Associate Director, National Institute for Health and Care Excellence</td>
<td>All</td>
</tr>
<tr>
<td>James Mahon</td>
<td>Evidence Review Group representative, Liverpool Reviews and Implementation Group</td>
<td>1 to 13</td>
</tr>
<tr>
<td>Fay McCracken</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>1 to 13</td>
</tr>
<tr>
<td>Kate Moore</td>
<td>Project Manager, National Institute for Health and Care Excellence</td>
<td>All</td>
</tr>
<tr>
<td>Professor David Snead</td>
<td>Pathologist and Clinical Lead, Clinical Expert, nominated by Royal College of Pathologists</td>
<td>1 to 13</td>
</tr>
<tr>
<td>Ashley West</td>
<td>Administrator, National Institute for Health and Care Excellence</td>
<td>All</td>
</tr>
</tbody>
</table>

**Non-public observers:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Institute</th>
<th>Present for Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Dent</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>1 to 16</td>
</tr>
</tbody>
</table>
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (CDF review of TA447) and atezolizumab for treating metastatic urothelial cancer after platinum-based chemotherapy.

2. The Chair informed the Committee of the non-public observers at this meeting: Ross Dent, Ann Greenwood, Stephen O’Brien, Hayley Sharpe and Maroulla Whitely.

3. Apologies were received from Dr Matthew Bradley, Professor Paula Ghaneh, Dr Peter Hall, Sumithra Maheswaran and Mr William Turner.

Any other Business

4. None

Appraisal of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (CDF review of TA447) [ID1349]

Part 1 – Open session

5. The Chair welcomed the invited experts: Sophie Beale, Dr Martin Forster, Lesley Holland, James Mahon and Professor David Snead to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Merck Sharp and Dohme to the meeting.

7. The Chair asked all Committee members to declare any relevant interests
7.1. Dr Nabeel Alsindi, Dr Aomesh Bhatt, Professor David Bowen, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Rebecca Harmston, Dr Robert Hodgson, Dr Bernard Khoo, Professor Gary McVeigh, Dr David Meads, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Paula Parvulescu, Dr Lindsay Smith and Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (CDF review of TA447).

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (CDF review of TA447).

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

9.1. Sophie Beale, Dr Peter Clark, Dr Martin Forster, Lesley Holland, James Mahon and Professor David Snead all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (CDF review of TA447).

10. The Chair introduced the lead team, Professor Rachel Elliot, Mr Malcolm Oswald and Professor Oluwafemi Oyebode, who gave presentations on the clinical effectiveness and cost effectiveness of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (CDF review of TA447).

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session
14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (CDF review of TA447).

15.1. The committee decision was based on consensus.

16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of atezolizumab for treating metastatic urothelial cancer after platinum-based chemotherapy [ID1327]

Part 1 – Open session

17. The Chair welcomed company representatives from Roche to the meeting.

18. The Chair asked all Committee members to declare any relevant interests

18.1. Dr Nabeel Alsindi, Dr Aomesh Bhatt, Professor David Bowen, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Rebecca Harmston, Dr Robert Hodgson, Dr Bernard Khoo, Professor Gary McVeigh, Dr David Meads, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Paula Parvulescu, Dr Lindsay Smith and Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating metastatic urothelial cancer after platinum-based chemotherapy.

19. The Chair asked all NICE Staff to declare any relevant interests.

19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating metastatic urothelial cancer after platinum-based chemotherapy.

20. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating metastatic urothelial cancer after platinum-based chemotherapy.
21. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

22. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

23. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

24. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

25. Discussion on confidential information continued. This information was supplied by the company.

26. The Committee continued to discuss the clinical and cost effectiveness of atezolizumab for treating metastatic urothelial cancer after platinum-based chemotherapy [ID1327].

26.1. The committee decision was based on consensus.

27. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

28. Thursday 8 March 2018, 10:00-14:30, at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.